Cardiovascular Systems, Inc. (CSI) is a medical technology firm dedicated to the creation and commercialization of advanced therapeutic solutions for individuals suffering from peripheral and coronary artery diseases, serving markets both within the United States and internationally. For peripheral artery disease (PAD), CSI offers a range of catheter-based systems designed to treat various types of arterial plaque, including severely calcified deposits, in arteries located both above and below the knee. These systems aim to provide improved outcomes compared to conventional surgical, interventional, and pharmacological treatments. The company also provides supplementary peripheral support products. Regarding coronary artery disease (CAD), CSI supplies the Diamondback 360 Coronary Orbital Atherectomy System (OAS). This specialized device is engineered to aid in the successful placement of stents in CAD patients who present with heavily calcified coronary artery lesions and are deemed suitable candidates for percutaneous transluminal coronary angioplasty or stenting procedures. Furthermore, CSI manufactures and distributes essential procedural accessories such as guidewires, catheters, balloons, and embolic protection systems, along with other supporting products for its OAS technology. In a collaborative effort, Cardiovascular Systems, Inc. has partnered with Chansu Vascular Technologies, LLC, focusing on the development of innovative everolimus drug-coated balloons for both peripheral and coronary applications. Originally established in 1989 as Shturman Cardiology Systems, Inc., the company officially adopted its current name, Cardiovascular Systems, Inc., in January 2003. Its corporate headquarters are located in Saint Paul, Minnesota.